Scienture Holdings Inc. outlined its outlook for the first quarter of 2026, expecting continued sequential growth in prescription volumes and adoption of ARBLI™, its FDA-approved oral suspension of losartan potassium. The company anticipates improved commercial efficiency as initial launch investments begin generating recurring demand. Scienture also projects further expansion of payer and pharmacy engagement, which is expected to broaden patient access across both commercial and government sectors. The company reported a significant strengthening of its balance sheet in the last quarter, including a substantial reduction in outstanding debt and an increase in its cash position to approximately $7.0 million as of December 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9647679-en) on February 03, 2026, and is solely responsible for the information contained therein.